# ClinicalTrials.gov record NCT00422058

> PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00422058-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00422058-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00422058-liraglutide-v1.json
- Content SHA-256: `b30d0e03e21576624c02b6a8299158e9311938e1a6be64fb741408dbc2fcaec6`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00422058 ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

## Sources

<a id="source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa"></a>
- **ClinicalTrials.gov record NCT00422058 · retained source version 2017-11-01:d2810fdb94aaad83aa65edb19700814dd2561b3d9e562d1099bb77a78ed0c4e1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00422058) (`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00422058." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00422058-liraglutide-v1.json SHA-256: b30d0e03e21576624c02b6a8299158e9311938e1a6be64fb741408dbc2fcaec6.